NexBio's Fludase influenza vaccine shows promising results

NexBio's lead drug candidate Fludase has shown encouraging results in a Phase 2 clinical trial by significantly reducing the amount of influenza virus in patients receiving the drug compared to those who took a placebo.

The drug, also known as DAS181, is designed to block a receptor that all flu virus strains use to enter cells in the airways and comes in the form of a powdered inhaler treatment. The protein molecule is being tested as a possible flu vaccine and a treatment for those already infected with the virus, Sign On San Diego reports.

"These positive clinical results with our flagship product are very exciting and mark an important initial corporate milestone," Dr. Fang Fang, president of research and development at NexBio, said in a statement, according to Sign On San Diego.

The 297 participants in the Phase 2 trial tested positive for several influenza A and B strains of the virus. Close to half of the patients received the drug as either a single 10 milligram dose or as three 10 milligram doses given once a day.

Monday's report of the results came 10 days after federal agents raided the privately owned company's headquarters in connection to a white collar criminal investigation. Federal authorities have yet to provide more information about the investigation and NexBio officials haven't responded to questions about the company's involvement in the case.

"I want to thank all my NIAID colleagues who have not only provided the funding to support DAS181 development from its infancy, but who have also worked with us collaboratively to obtain these important results," Fang said, according to Sign On San Diego.

The lead researchers of the trial plan to discuss the work in September at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Chicago.